Table 3

Stratified analyses of multivariable-adjusted logistic regression models for the association between aPL and smoking, presented as ORs and 95% CI

	aCL IgG	aCL IgM	aCL IgA	aβ₂GP1 IgG	aβ₂GP1 IgM	aβ₂GP1 IgA	LA	Triple positivity
Females (n=316)†
Current (n=57)	1.0 (0.4–2.5)	2.0 (0.9–4.2)	2.0 (0.9–5.9)	1.1 (0.4–2.8)	2.2 (0.9–5.9)	1.8 (0.8–4.2)	2.7 (1.1–6.6)*	2.3 (0.9–8.8)
Former (n=109)	3.1 (1.6–6.1)*	1.0 (0.5–2.1)	1.6 (0.8–3.2)	2.7 (1.3–5.8)*	0.7 (0.2–1.9)	2.0 (0.9–4.0)	4.2 (2.1–9.2)*	4.1 (1.7–11.1)*
Warfarin treated (n=55)
Current (n=9)	3.5 (0.4–33.0)	2.1 (0.3–5.5)	4.2 (0.5–37.4)	1.8 (0.07–25.9)	1.0 (0.04–13.9)	5.4 (0.7–51.2)	5.3 (0.8–42.4)	2.0 (0.07–33.0)
Former (n=26)	12.8 (2.6–96.5)*	1.2 (0.3–5.5)	4.0 (0.9–23.6)	18.0 (2.9–199.7)*	0.98 (0.9–8.9)	5.2 (1.1–34.4)*	18.1 (3.8–123)*	18.3 (3.0–203)*
Untreated (n=312)
Current (n=60)	1.2 (0.4–3.0)	2.0 (0.8–4.6)	1.9 (0.8–4.3)	1.5 (0.6–3.8)	2.5 (0.9–6.5)	1.6 (0.7–3.8)	1.6 (0.6–4.1)	3.2 (1.1–10.5)*
Former (n=101)	2.0 (0.96–4.4)	0.8 (0.3–2.0)	1.2 (0.4–2.3)	2.0 (0.9–4.6)	0.4 (0.09–1.5)	1.3 (0.6–2.9)	1.6 (0.7–3.7)	2.0 (0.6–6.3)
Previous event
Yes (n=96)
Current (n=20)	2.3 (0.5–11.6)	1.2 (0.2–6.0)	2.9 (0.7–12.5)	2.6 (0.4–17.5)	0.7 (0.03–8.9)	3.3 (0.8–15.2)	1.8 (0.5–7.5)	1.4 (0.3–5.2)
Former(n=41)	10.6 (3.1–45.4)*	1.9 (0.6–7.0)	3.4 (1.1–12.3)*	8.4 (2.4–38.5)*	1.8 (0.3–14.6)	4.5 (1.4–17.7)*	7.9 (2.7–26.6)*	3.9 (1.1–4.1)*
No (n=271)
Current (n=49)	1.2 (0.4–3.2)	2.6 (1.1–6.1)*	1.7 (0.7–4.3)	1.3 (0.4–3.7)	3.0 (1.1–8.2)*	1.4 (0.5–3.5)	2.2 (0.8–5.7)	3.9 (1.1–14.1)*
Former (n=86)	1.5 (0.6–3.6)	0.8 (0.3–1.9)	0.8 (0.3–2.0)	1.4 (0.5–3.7)	0.3 (0.05–1.2)	0.98 (0.4–2.4)	1.3 (0.5–3.4)	1.3 (0.3–5.2)
Patients who stopped smoking the same year as/after the first event excluded† (n=349)
Current (n=69)	1.3 (0.6–3.0)	2.1 (0.97–4.3)	1.9 (0.9–4.0)	1.4 (0.6–3.2)	2.2 (0.9–5.5)	1.8 (0.8–3.8)	2.1 (0.9–4.6)	2.7 (0.96–7.8)
Former (n=109)	2.2 (1.1–4.3)*	1.0 (0.5–2.1)	1.03 (0.5–2.2)	2.2 (1.1–4.6)*	0.6 (0.2–1.8)	1.2 (0.6–2.6)	2.1 (1.0–4.2)*	1.5 (0.2–2.1)

*p≤0.05.
†Analyses of subsets of patients that is, per definition not stratified analyses. For abbreviations of antiphospholipid antibodies (aPL), see table 1.